A Phase 4 interventional study of Pregabalin and Oxcarbazepine in Neuralgia and Spinal Cord Injury, sponsored by Ju Seok Ryu. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-08-20.
Sponsored by Ju Seok Ryu · Phase 4, Interventional, and Treatment
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one is the 38th largest by enrollment, is one of 3 that started in 2012, is one of 12 in phase 4, and was the 30th registered.
1,100 studies on the registry are indexed under Neuralgia; 241 are open to participants now.
This study's enrollment of 63 is above the median of 52 across 831 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Each count lists the studies.
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 152 Neuralgia studies recruiting now, 76 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →50 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2012.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
21 of 50 have an industry lead sponsor. The 10 most frequent:
Ju Seok Ryu is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Ju Seok Ryu has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
Inclusion criteria
Method
In the present study, pharmacologic treatment included pregabalin and oxcarbazepine.
Stop medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), tramadol and anti-spastic drugs (baclofen, tizanidine) and other medications known to have effect on pain and the central nervous system prior to the study for at least 3 days.
Pain intensity (VAS score)
4 spontaneous characters
evoked pain
Location of neuropathic pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregabalin and Oxcarbazepine
Drug: Pregabalin and Oxcarbazepine
Drug pages: Pregabalin · Oxcarbazepine
Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day. Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.
Also known as: Lyrica and Oxcarb
Symptom based treatment of neuropathic pain
Pain intensity using Visual analogue scale (0\~100)
Time frame: 2 week later
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Oxcarbazepine
Ju Seok Ryu